Shizhiyuan, a subsidiary of Shenlian Biotech (688098.SH), obtained a patent for the invention of HIV monoclonal antibodies

Zhitong Finance App News, Shenlian Biotech (688098.SH) announced that Yangzhou Shizhiyuan Biotechnology Co., Ltd. (“Shizhiyuan” for short), recently obtained an invention patent issued by the State Intellectual Property Office for “treatment and functional cure of HIV infection by mediating competitive HIV entry suppression through monoclonal antibodies against CD4”. This invention patent relates to the CD4 monoclonal antibody, its composition, and methods of using this composition to prevent, treat and functionally cure HIV infection.

According to the announcement, the monoclonal antibody drug UB-421, which is currently being developed to treat HIV in the pipeline, has a novel mechanism of action. By binding to the CD4 receptor domain 1 on the surface of target T cells, the drug effectively blocks the HIV virus from entering host cells by means of competitive inhibition. Since UB-421 does not directly target viral genes, compared to existing AIDS drugs currently on the market, UB-421 is less likely to cause viral drug-resistant mutations, and has an immunomodulatory effect. UB-421 will mainly conduct research in the fields of multiple drug resistance and functional healing in China.